- Previous Close
11.60 - Open
11.60 - Bid 11.35 x --
- Ask 11.55 x --
- Day's Range
11.30 - 11.70 - 52 Week Range
11.30 - 27.00 - Volume
200,525 - Avg. Volume
166,726 - Market Cap (intraday)
882.488M - Beta (5Y Monthly) -0.40
- PE Ratio (TTM)
-- - EPS (TTM)
-0.08 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company also develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.
www.taiwanj.comRecent News: 6549.TWO
Performance Overview: 6549.TWO
Trailing total returns as of 6/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6549.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6549.TWO
Valuation Measures
Market Cap
867.66M
Enterprise Value
810.00M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
38.15
Price/Book (mrq)
12.96
Enterprise Value/Revenue
35.62
Enterprise Value/EBITDA
-546.33
Financial Highlights
Profitability and Income Statement
Profit Margin
-26.59%
Return on Assets (ttm)
-5.39%
Return on Equity (ttm)
-8.73%
Revenue (ttm)
22.74M
Net Income Avi to Common (ttm)
-6.05M
Diluted EPS (ttm)
-0.08
Balance Sheet and Cash Flow
Total Cash (mrq)
58.83M
Total Debt/Equity (mrq)
1.75%
Levered Free Cash Flow (ttm)
2.15M